Phase 3RecruitingINTERVENTIONAL
Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH
ClinicalTrials.gov · NCT07795164 · Registry updated: 2026-09-23
- Condition / research focus
- Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- Sponsor
- Altimmune, Inc.
- Countries with listed sites
- United States
- Registry dates and results
- Start: 2026-07-30. Completion: 2032-12 (may be estimated). No results posted in this registry response.
Products and interventions (2)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Pemvidutide (drug)
- Placebo (other)
Where the study takes place — 9 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.
- Altimmune Clinical Study Site
North Little Rock, Arkansas, United States
Site recruitment: Recruiting